The mechanism of action of ciabimatoprost involves its interaction with specific prostaglandin receptors on the surface of cancer cells. By binding to these receptors, ciabimatoprost can inhibit the proliferation of cancer cells and induce apoptosis, or programmed cell death. Additionally, ciabimatoprost may interfere with angiogenesis, the process by which tumors develop new blood vessels to sustain their growth. This dual action makes ciabimatoprost a promising candidate for cancer therapy.
